China News Service/China News Service via Getty Images Introduction A quarter has passed since I initiated a “Buy” rating on Organon & Co. (NYSE:OGN). In this time the stock has gained around 63% – that’s 7 times more than the return of the S&P 500 Index (SPX) (SPY) in the same period: Seeking Alpha, the…
Rasica The Company And The Stock Organon & Co. (NYSE:OGN) is a global healthcare company dedicated to enhancing women’s health at every stage of their lives. The company focuses on developing and delivering innovative health solutions, including a diverse portfolio of prescription therapies and medical devices within women’s health, biosimilars, and established brands. With a…
PM Images Investment Overview Organon & Co. (NYSE:OGN), formed via Pharma giant Merck & Co.’s (MRK) spinout of its Established Brands, Women’s Health and Biosimilars divisions, announced its Q3 earnings on Thursday, November 2. I covered Organon’s Q2 earnings in a deep dive note for Seeking Alpha in August. I gave the stock a “Hold”…
ISerg/iStock via Getty Images Introduction It’s time to discover a stock I have never covered before. Organon & Co. (NYSE:OGN) is a woman’s health-focused healthcare spin-off that isn’t doing so well – at least when looking at its stock price. FINVIZ OGN shares are down 30% year-to-date and more than 40% below their 52-week highs….